Today, Prolight Diagnostics announces that it has hired Karl Bullen as Head of Manufacturing in its subsidiary Psyros Diagnostics to ensure the company's internal competence in manufacturing.
"It gives us immense satisfaction that our company can attract such senior and competent staff. We consider it a testament to the strong market we see for our diagnostics. Karl Bullen has extensive manufacturing experience, which will prove very valuable as we now plan production for our subsidiary Psyros Diagnostics," says Ulf Bladin, CEO of Prolight Diagnostics.
"I am very pleased to join Psyros. The market for point-of-care testing systems is enormous and needs new technology. This is where I see that Prolight and Psyros, with their cutting-edge technologies, have a great need to fill, and it will be exciting to contribute to that journey," says Karl Bullen, incoming Head of Manufacturing for Psyros Diagnostics.
Karl Bullen will take office on 31 October and joins from Recipharm, where he was Head of Operations.
For further information, please contact:
The following documents can be retrieved from beQuoted
Prolight Diagnostics Pressrelease 2022-10-04 en.pdf
Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible near-patient testing systems, Point-of-Care Testing (POCT), which is IT based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in health centres, nursing homes, emergency departments, intensive care units, and other settings, enabling testing close to the patient and with rapid test results. With this technology, health care providers will be able to sort out patients in need of rapid treatment from patients that, for example, are not having a heart attack. The sales value in the POCT area amounted to USD 34.6 billion in 2021 and is growing strongly.
The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.